This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Autolus Limited. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Innovations of Lukas Stanczuk
Introduction
Lukas Stanczuk is a notable inventor based in London, GB. He has made significant contributions to the field of biotechnology, particularly in the development of advanced cellular technologies. His work focuses on enhancing the capabilities of immune cells to target and eliminate cancer cells.
Latest Patents
Lukas holds a patent for a novel cell design. The patent describes a cell that comprises a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR), along with a polypeptide capable of co-localizing a beta-2 microglobulin component of a MHC class I molecule with an intracellular signaling domain within the cell. This innovation has the potential to improve the efficacy of immunotherapies.
Career Highlights
Lukas is currently employed at Autolus Limited, a company that specializes in developing next-generation T-cell therapies for cancer treatment. His role involves research and development, where he applies his expertise to create innovative solutions in the field of immunotherapy.
Collaborations
Lukas collaborates with talented professionals in his field, including Martin Pulé and James Sillibourne. Their combined efforts contribute to the advancement of cellular therapies and the fight against cancer.
Conclusion
Lukas Stanczuk is a pioneering inventor whose work in cellular technology is paving the way for new cancer treatments. His patent and contributions to Autolus Limited highlight his commitment to innovation in biotechnology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile